Drug Patents owned by Teva Pharms Intl
1. List of Amrix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829121 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US9375410 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US9399025 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US8877245 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US7544372 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US7820203 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US7790199 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months from now) | |
| US7387793 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Feb, 2025
(1 year, 8 months from now) | |
Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 February, 2007
Treatment: Relief of muscle spasm
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
AMRIX family patents
11
United States
2. List of Synribo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(3 years from now) | |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)
Dosage: POWDER;SUBCUTANEOUS
SYNRIBO family patents
2
Cyprus
2
Denmark
2
Portugal
2
Spain
2
Japan
2
United States
2
Austria
2
Hong Kong
2
European Union
1
Germany
1
Canada
1
Australia
1
IB
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic